Lori Mull, PhD
Psomagen Spatial Biology, Single-Cell & Proteomics Product Manager
Presenting Psomagen's proteomics portfolio

Dr. Mull served as a technical support scientist for multiple product lines including protein and antibody development for 15 years. That experience includes establishing and conducting the daily operations of an applications laboratory at a medical device company.  Dr. Mull worked as the Pharma & CRO field application scientist (FAS) at NanoString where she learned spatial biology by supporting the novel GeoMx platform and biostatistics by supporting the nCounter platform. Dr. Mull provided scientific support for the analytical testing group of a contract development and manufacturing company (CDMO) specializing in cell and gene therapy. With her expansive scientific background and experience in regulated environments, Dr. Mull has the expertise to deliver technical support, troubleshooting, and operational guidance for both of her product lines.  

Dr. Abhay Moghekar
High throughput CSF proteomics identifies neuronal hyperactivity precedes amyloid conversion in preclinical Alzheimer's disease

Dr. Abhay Moghekar is an Associate Professor of Neurology, Neurosurgery, and Otolaryngology at Johns Hopkins University and the Research Director and a practicing neurologist at the Cerebrospinal Fluid Center at Johns Hopkins Medicine. His research interests include identifying biomarkers of neurodegenerative disorders, including Alzheimer's disease and Hydrocephalus. He is the Fluid Biomarker Core Leader for the Johns Hopkins Alzheimer's Disease Research Center and his lab serves as the Biomarker Core for several NIH funded studies including BIOCARD, BLSA, PENS and PAN.

Dr. Chris deFilippi
From circulating single biomarkers to targeted discovery proteomics for identifying effect measure modifiers to predict the efficacy of a physical therapy intervention to improve physical function in older adults after a heart failure hospitalization

Dr. Christopher deFilippi is a Professor of Medicine and Pathology at the University of Maryland School of Medicine. He is the Director of Cardiovascular and Biomarker research for the University of Maryland Institute of Health Computing. He is also the co-director of Clinical Core Research Laboratory at the University of Maryland Baltimore. His research and clinical interests have focused on cardiac biomarkers over the course of his career, publishing over 300 papers and receiving NIH funding to study biomarkers. Much of his effort has focused on using biomarkers for risk-stratification and prognosis with asymptomatic ambulatory adults to patients with acute myocardial infarction, heart failure and chronic kidney disease. His work now frequently includes discovery-based proteomics for biomarker discovery with a focus on identify novel circulating proteins that are powerful effect measure modifiers that can stratify the efficacy of treatments across different clinical populations.

Dr. Allen D. Everett
Plasma proteomics discovery of pulmonary hypertension severity biomarkers

Allen D. Everett, MD is a Professor of Pediatrics and a Pediatric Cardiologist at Johns Hopkins where he is the Director of the Pediatric Proteome Center. Since joining the Johns Hopkins faculty in 2003, Dr. Everett has become the program leader at the Johns Hopkins in Pediatric biomarker discovery, initially in sickle cell disease and subsequently in other pediatric clinical conditions (birth injury, congenital heart disease repair, ECMO, prematurity and pulmonary hypertension) and PI or Co-PI on multiple NIH funded R01 studies. Dr. Everett is co-developer of PedCathTM cardiac catheterization software with Scientific Software Solutions which has been translated into five languages, and has five US pulmonary hypertension and brain injury biomarker patents filed or issued and brain injury biomarkers licensed to ImmunArray, Ltd.  Dr. Everett is a fellow of the American Heart Association, American College of Cardiology, Society for Cardiac Interventions and Angiography, Society for Pediatric Research, International Society for Heart and Lung Transplant and Pulmonary Vascular Research Institute and USHUPO.  

Dr. Jill Koshiol
Gaining Insight into Hepatobiliary Cancers through Immune-related Markers

Dr. Jill Koshiol is a Senior Investigator in the Infections and Immunoepidemiology Branch of the Division of Cancer Epidemiology and Prevention. She focuses on biliary tract cancers, which are linked to both infections and inflammation. Biliary tract cancers are rare in much of the world, but there are hotspots where these cancers constitute a major public health burden. Immune response is likely central to the carcinogenesis process. By elucidating the epidemiology of biliary tract cancers, Dr. Koshiol hopes to identify new opportunities for cancer prevention and early detection that can be translated into public health impact, particularly in high-risk populations.